RxDoctor Payments Data

Daniel Gutman, MD

Pulmonary Disease · Asheville, NCNPI 1174899801

Payments from drug & device makers

$1,189in general payments, 2019–2025

Across 65 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$299
  • GSK$240
  • Actelion Pharmaceuticals US, Inc.$117
  • Mylan Specialty L.p.$85
  • Sanofi$67
  • Regeneron Healthcare Solutions, Inc.$65
  • plus $315 from 8 others

What the payments were for

  • Food & beverage$1,15197%
  • Education$383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,189 in reported general payments places this provider in the 45th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$92,107
Medicare patients
387
Services billed
914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter279$204,911
NucalaMepolizumab41$161,629
Dupixent PenDupilumab13$57,382
Dupixent SyringeDupilumab12$52,913
Breztri AerosphereBudesonide/Glycopyr/Formoterol63$43,790
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr78$37,244
Stiolto RespimatTiotropium Br/Olodaterol Hcl66$35,174
Spiriva RespimatTiotropium Bromide25$15,084
Breo ElliptaFluticasone/Vilanterol35$14,864
SymbicortBudesonide/Formoterol Fumarate51$12,850
Albuterol Sulfate HfaAlbuterol Sulfate165$4,963
Wixela InhubFluticasone Propion/Salmeterol51$3,226
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,944
Ventolin HfaAlbuterol Sulfate20$1,144
Prednisone90$409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta$240$418,648433 claims
AstraZenecaBreztri Aerosphere, Symbicort$44$56,640114 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$299$50,25891 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →